Navigation Links
Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
Date:5/7/2008

tive household survey, which used a lay-administered diagnostic interview to assess a wide range of DSM-IV disorders. ADHD is a neurobiological disorder that manifests as a persistent pattern of inattention and/or hyperactivity-impulsivity that is more frequent and severe than is typically observed in individuals at a comparable level of development. To be properly diagnosed with ADHD, a child needs to demonstrate at least six of nine symptoms of inattention; and/or at least six of nine symptoms of hyperactivity/impulsivity; the onset of which appears before age 7 years; that some impairment from the symptoms is present in two or more settings (e.g., at school and home); that the symptoms continue for at least six months; and that there is clinically significant impairment in social, academic or occupational functioning and the symptoms cannot be better explained by another psychiatric disorder.

Although there is no "cure" for ADHD, there are accepted treatments that specifically target its symptoms. The most common standard treatments include educational approaches, psychological or behavioral modification, and medication.

For further information please contact:

Porter Novelli for Shire

Sherry Goldberg

212.601.8279

917.923.4010 (mobile)

sherry.goldberg@porternovelli.com

Michelle Park

212.601.8248

212.729.4577 (mobile)

michelle.park@porternovelli.com

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540
2. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
3. Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
4. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
5. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
6. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
7. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
8. SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients
9. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
10. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
11. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... -- AVAX Technologies, Inc. (Pink Sheets: AVXT) ("AVAX" ... closed a bridge loan financing (the "2009 Financing") ... Agreement (the "Agreement") with Firebird Global Master Fund, ... sold a convertible promissory note, due June 30, ... and issued a warrant to purchase an aggregate ...
(Date:12/16/2009)... YORK, December 16 International, ... publication of GFT505 (80 mg/day),data presented ... internationally,recognized expert scientists and clinicians critically ... continuing role of generic lipid-modifying,treatments, fenofibrate ... is commonly observed in patients with ...
(Date:12/16/2009)... 16 Boston Scientific Corporation (NYSE: ... Directors has elected Nelda Connors as a Director. ... Electrical and Metal Products division of Tyco International. ... holding several positions in operations and general management. ... number of executive and management capacities with Ford, Chrysler ...
Breaking Medicine Technology:AVAX Technologies, Inc. Closes Bridge Financing 2AVAX Technologies, Inc. Closes Bridge Financing 3AVAX Technologies, Inc. Closes Bridge Financing 4International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia 2International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia 3Boston Scientific Announces Election of Nelda Connors to Its Board of Directors 2Boston Scientific Announces Election of Nelda Connors to Its Board of Directors 3Cooling treatment after cardiac arrest is cost effective Penn study shows 54589 1Cooling treatment after cardiac arrest is cost effective Penn study shows 54589 2Guided care reduces cost of health care for older persons with chronic conditions 54587 1Guided care reduces cost of health care for older persons with chronic conditions 54587 2 Netroots Nation 2009 Straw Poll Results 54585 1 Netroots Nation 2009 Straw Poll Results 54585 2 Netroots Nation 2009 Straw Poll Results 54585 3 Netroots Nation 2009 Straw Poll Results 54585 4 Netroots Nation 2009 Straw Poll Results 54585 5 Netroots Nation 2009 Straw Poll Results 54585 6 Netroots Nation 2009 Straw Poll Results 54585 7
(Date:12/16/2009)... Inc. (Nasdaq: SMBL ) announced today that its ... program of up to $25 million, to begin in ... have in the prospects of our Company and shows ... our shareholders, while at the same time making prudent ... Chairman and Chief Executive Officer. ,, Any purchases under ...
(Date:12/16/2009)... Ga., Dec. 16 Immucor, Inc. (Nasdaq: ... systems to the blood transfusion industry, today announced that ... board as a new independent director, effective January 1, ... blood banking and transfusion medicine for more than 30 ... Medicine at the University of Virginia School of Medicine. ...
(Date:12/16/2009)... Dec. 16 As a result of C3: ... new peer reviewed cancer research program is included in ... ,, This new cancer research program will research cancers, ... breast, prostate, lung and ovarian cancer research programs run ... ,, The $15 million in funding for ...
(Date:12/16/2009)... Wellcome Trust Sanger Institute announce the first comprehensive analyses ... by mutations in the DNA of cancer cells which ... a malignant melanoma and a lung cancer, reveal for ... genomes of two cancers. , Lung cancer causes around ... associated with smoking. The number of mutations found suggest ...
(Date:12/16/2009)... Coalition Urges Lawmakers to Ensure and Encourage Access to Quality, Cost-Effective ... ... -- For months, members of Congress have debated the best ways ... part of health care reform. An important part of the ... full range of health care providers besides doctors of medicine (MDs) ...
Breaking Medicine News(10 mins):Health News:Smart Balance Authorizes Stock Repurchase Program 2Health News:Immucor Appoints New Board Director 2Health News:House Creates New Cancer Research Program 2Health News:House Creates New Cancer Research Program 3Health News:Lung cancer and melanoma laid bare 2Health News:Lung cancer and melanoma laid bare 3Health News:Lung cancer and melanoma laid bare 4Health News:Lung cancer and melanoma laid bare 5Health News:Lung cancer and melanoma laid bare 6Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 2Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 3Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 4Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 5
... of the currently used multiple sclerosis drugs can be ... //. Previously, the same group of researchers had established ... lower the development of full-blown form of multiple sclerosis. ... documented in animal models of the disease, so far, ...
... to board a 500-capacity British cruise vessel, Funchal that has ... presently off the West Australian coast, and will host the ... board have been infected by a contagious flu. ,The ... said, "The Department of Health is sending a team of ...
... at the Medway Maritime Hospital in Kent has blasted the NHS ... since his hospital cannot afford to do more surgery. // ... person to turn up when there should be three in the ... - while we're paid, when we could be seeing patients," Dr ...
... in Mumbai and many more with the symptoms of the ... said that more doctors has been pressed into service to ... ,Around 50 people were admitted to hospitals Wednesday, particularly in ... count, 90 people were admitted to hospitals and five in ...
... common to feel down in the dumps, and under weather, when ... But there is a huge gap between feeling low and depression, ... one in every ten people in the United Kingdom, and falls ... to be more prone to depression., ,Depression is a ...
... man in central-western NSW, both suspected to have contacted meningococcal ... The man and the baby, who hail from Cobar and ... ,It has not been possible to relate both the ... Dr.Tony Brown of the Greater Western Area Health Service. In ...
Other Medicine News:Health News:Drug Combo Improves Performance Of Multiple Sclerosis Drug 2
... FiberStick, available in #2 or 2-0 sizes, ... waxed end. Used in conjunction with small ... needles, it makes suture passing easy. By ... it alleviates the need for a monofilament ...
... is a suture option for ... diameter looped FiberWire products allow ... extensor tendon repairs while reducing ... passes. FiberLoop is available with ...
... the Flowmaster. It is a new portable digital ... ease of use, simplicity and cost effectiveness are ... it now very easy to give a patient ... want and data will be send wirelessly to ...
... The Flowstar is a compact and ... flowstudies. The investigation starts automatically when ... and volume scales can be adjusted ... are user selectable. Siroky flow plots ...
Medicine Products: